<TABLE cellSpacing=4 cellPadding=6 width=538 border=0><TBODY><TR><TD vAlign=top align=left>I received my first Herceptin/chemo combo as a weekly tx when diagnosed with recurrent bc, when I had been postmenopausal for 5 years. I've since alternated from weekly to 3 weekly to 2 weekly and now back to weekly.
Here's an excerpt from an article regarding the dosage amount for 3 weekly:
</TD></TR><TR><TD vAlign=top align=left>OncoLink: Herceptin treatment every three weeks as safe, effective as weekly dosing</TD></TR><TR><TD><SMALL>Last Updated: 2002-03-22 13:31:13 EST (Reuters Health) </SMALL>BARCELONA, Spain (Reuters Health) - Based on preliminary results of a phase II study presented Thursday at the 3rd European Breast Cancer Conference here, Herceptin (trastuzumab, AstraZeneca) administered every three weeks is as safe and effective as administration every week.
Dr. Josep Baselga, chief investigator of the study and head of oncology at the Hospital Vall d'Hebron in Barcelona, explained to Reuters Health that this finding "is going to make the treatment more comfortable" for women who undergo this therapy for HER2-positive tumors.
The researchers recruited 105 breast cancer patients with at least two metastases, the majority of which were in the lung and liver. The women were given an initial dose of Herceptin of 8 mg/kg of body weight, followed by a dose of 6 mg/kg every 3 weeks. The usual dose of the drug when administered weekly is 2 mg/kg.
The observed response rate was 23%--comparable, according to Dr. Baselga, to that observed with weekly administration. Side effects were very similar to those reported with weekly administration, and there were no "unexpected adverse effects" reported.
The oncologist commented to Reuters Health that the HERA clinical trial that includes 3000 subjects will conclude in 1 month. The trial compares the two dosing schedules of Herceptin in breast cancer patients without metastases.
</TD></TR></TBODY></TABLE>
__________________
Sept.'99 - Dx.Stage IIIB, IDC ER/PR-, HER2+++ by IHC, confirmed '04 by FISH. Left MRM, AC x's 4, Taxol x's 4, 33 Rads, finishing Tx May 2000. Jan.'01 - local/regional recurrence, Stage IV. Herceptin/Navelbine weekly till NED August 2001, then maintenance Herceptin. Right Mast. April 2002. Local/Regional recurrence April '04, Herceptin plus/minus chemo until May '07. Gemzar added from Feb.'07-April '07; Tykerb/Abraxane until August '07, back on Herceptin plus Taxotere and Xeloda Sept. '07. Stopped T/X Nov. '07, stopped Herceptin Dec. '07, started Avastin/Taxol/Carboplatin Dec. '07. Progression in chest skin, stopped TAC March '03, started radiation.
Herceptin has served as the "Backbone" of my treatment strategy for over 6 years, giving me great quality of life. In 2005, I was privileged to participate in the University of Washington/Seattle HER2 Vaccine Trial.
|